THC FARMACEUTICALS WELCOMES JORDAN DESPANIE, PhD TO ITS ADVISORY BOARD.
Thousand Oaks, CA — May 15, 2019 — InvestorsHub NewsWire — CBDual Biotechnology Corp., a subsidiary of THC Farmaceuticals, Inc. (OTC PINK: CBDG) is pleased to announce the appointment of Jordan Despanie, PhD to its Advisory Board. Bringing over a decade of research experience, Dr. Despanie completed his Pharmaceutical Sciences PhD at the University of Southern California following a BS in Biology from Louisiana State University.
Dr. Despanie began his biomedical career at LSU investigating molecular therapies such as oncolytic virotherapy and antiviral gene silencing before joining Johns Hopkins Hospital to probe how defective protein trafficking contributes to cystic fibrosis.
His dissertation, “Tubulin-based fusion proteins as multifunctional tools”, detailing a novel class of chemotherapy nanomedicines to combat triple-negative breast cancers (an aggressive disease subtype for which there are currently no targeted treatments) received over $178,000 in NIH grant funding.
In 2014, Dr. Despanie also founded S-aima Biopharmaceutics LLC, a biotech startup which sought to develop an artificial blood nanomedicine for temporary blood replacement on the battlefield and during civilian emergencies.
An enthusiastic Dr. Despanie affirms, “This is a unique opportunity to leverage my passion for nanomedicine towards designing CBD formulations that will undoubtedly grant us a competitive edge in the marketplace.”
“We are thrilled and honored to have Dr. Jordan Despanie join CBDG. We look forward to working with him as we take CBDG’s science to the next level”, says Mike Gravel, Chairman and CEO of THC Farmaceuticals, Inc.
About CBDual Biotechnology
CBDual Biotechnology Corp. is owned by THC Farmacuticals, a publicly traded company
(OTC: CBDG), which is a biotechnology company with propriety technology for enhanced oral delivery methods. This technology for enhanced oral delivery of bioactive cannabinoids and other delivery methods. This technology promotes overall oral health due to higher effectiveness of the delivery methodology. The company was founded in 2016 and is headquartered in California, with its R &D in the US and Israel.
This press release contains “forward-looking statements.” Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.